06622.HK (Zhaoke Ophthalmology) repeatedly fell 5.8% to 15.82 yuan in dark trading; the stock opened 7.6% lower at 15.52 yuan, continued to "dive", high or low, 15.6 yuan / 14.36 yuan, half-day income 14.50 yuan, lower than the listing price 16.8 yuan, 13.7% lower, half-day turnover of 25.9 million shares, involving 395.7 million yuan.

Mega Ophthalmology, spun off by 00950.HK, is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of treatments to meet the huge medical demand gap in the mainland. The company's goal is to become a market leader in China and neighboring ASEAN. A total of nearly 124 million shares have been sold, and eight cornerstone investors, including CaaS Capital, GIC, Aobo Capital, Golden Valley, Jennison, Mass Ave, VMS and Matthews, have been introduced to subscribe a total of 25.461 million shares. 10% of the public offering has been 55 times oversubscribed, the share of the callback mechanism has been increased to 40%, and the subscription success rate is 25%. The shares are priced at the upper limit of the IPO range, and the net capital raised is expected to be about 1.942 billion yuan. it is mainly used for clinical development and commercialization of the group's core products, funding for other continuous R & D activities and commercialization of drugs waiting for research and development, and production line expansion for advanced production facilities located in Nansha. The co-sponsors of the listing are Goldman Sachs and Jefferies.